HRT Financial’s Syndax Pharmaceuticals SNDX Stock Holding History

HRT Financial’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.08M	Buy	+88,904	New	+$1.93M	0.01%	1593
2025 Q4	–	Sell	-148,139	Closed	-$2.28M	–	3972
2025 Q3	$2.28M	Buy	148,139 +21,028	+17%	+$275K	0.01%	1074
2025 Q2	$1.19M	Sell	127,111 -17,923	-12%	-$197K	0.01%	1188
2025 Q1	$1.78M	Buy	145,034 +40,154	+38%	+$566K	0.01%	860
2024 Q4	$1.39M	Buy	104,880 +51,454	+96%	+$881K	0.01%	911
2024 Q3	$1.03M	Buy	+53,426	New	+$1.1M	0.01%	1226
2023 Q4	–	Sell	-24,009	Closed	-$348K	–	3016
2023 Q3	$348K	Buy	24,009 +13,258	+123%	+$251K	﹤0.01%	1589
2023 Q2	$225K	Buy	+10,751	New	+$224K	﹤0.01%	1782
2022 Q2	–	Sell	-43,145	Closed	-$749K	–	3669
2022 Q1	$749K	Buy	+43,145	New	+$726K	0.01%	1262

Other funds holding SNDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

HRT Financial's SNDX Position: Q1 2026 in Review

HRT Financial opened a new position in Syndax Pharmaceuticals (SNDX) in Q1 2026: 88,904 shares worth $2.08M. The stake represents 0.01% of the portfolio and ranks #1593 among its holdings. This is a return to the name: HRT Financial previously reported a position in SNDX as recently as Q3 2025.

HRT Financial first reported a position in SNDX in Q1 2022 and has held it in 9 quarters since. The position peaked at $2.28M in Q3 2025. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

HRT Financial held 88,904 shares of Syndax Pharmaceuticals worth $2.08M as of Q1 2026.
Syndax Pharmaceuticals was a new HRT Financial position in Q1 2026.
Syndax Pharmaceuticals made up 0.01% of HRT Financial's portfolio in Q1 2026, its #1593 holding.
HRT Financial first reported a position in Syndax Pharmaceuticals in Q1 2022 and has held it in 9 quarters since.
HRT Financial's Syndax Pharmaceuticals position peaked at $2.28M in Q3 2025.
246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.